Nektar Therapeutics
NASDAQ: NKTRSan Francisco, US · Delaware corporation · 1 known investors
Nektar develops novel medicines targeting autoimmune and inflammatory conditions through immune science, aiming to restore immune balance. It operates in the biotechnology and immunology therapeutics space.
BiotechHealthtech
Founders & leadership
HW
Howard W. RobinExecutive
GM
Gil M. LabrucherieExecutive
MH
Maninder HoraExecutive
SK
Stephen K. DobersteinExecutive
JN
John NicholsonExecutive
JB
Jillian B. ThomsenExecutive
Board
LL
Lutz LingnauBoard director
RW
Roy WhitfieldBoard director
CA
Christopher A. KueblerBoard director
DL
Dennis L. WingerBoard director
JR
Jeff R. AjerBoard director
RS
R. Scott GreerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$880M disclosed across 2 rounds · 2018–2024
▶$30MraisedMar 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$30MraisedMar 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roy A WhitfieldDirector
- Mark A WilsonExecutive Officer
- Sandra GardinerExecutive Officer
- Jeffrey R AjerDirector
- Howard W RobinExecutive Officer, Director
- Diana M BrainardDirector
- Robert B ChessDirector
- R. Scott GreerDirector
- Jonathan ZalevskyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$850MraisedApr 2018 · 1 investors · PharmaceuticalsRule 506(b)
▶$850MraisedApr 2018 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lutz LingnauDirector
- Howard W. RobinExecutive Officer, Director
- Gil M. LabrucherieExecutive Officer
- Maninder HoraExecutive Officer
- Stephen K. DobersteinExecutive Officer
- John NicholsonExecutive Officer
- Roy WhitfieldDirector
- Jillian B. ThomsenExecutive Officer
- Christopher A. KueblerDirector
- Dennis L. WingerDirector
- Jeff R. AjerDirector
- R. Scott GreerDirector
- Robert ChessDirector
- Offering amount
- $850M
- Amount sold
- $850M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapMedscape65 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Healio53 shared keywordsHealio provides medical news, clinical data, and continuing medical education (CME) for healthcare professionals across specialties such as infectious disease and hepatology. It covers topics including biliary diseases, Ebola, and emerging outbreaks.
Seeking Alpha53 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with Nektar Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Nektar Therapeutics do?
- Nektar develops novel medicines targeting autoimmune and inflammatory conditions through immune science, aiming to restore immune balance. It operates in the biotechnology and immunology therapeutics space.
- Who are Nektar Therapeutics's investors?
- Nektar Therapeutics's investors include HEALTHCARE ROYALTY PARTNERS.
- How much funding has Nektar Therapeutics raised?
- Nektar Therapeutics has disclosed $880M raised across 2 rounds.
- Where is Nektar Therapeutics headquartered?
- Nektar Therapeutics is headquartered in San Francisco, US.